华东部分地区12岁以下儿童5型腺病毒感染状况调查——用于Ad5型重组载体疫苗或者基因治疗剂的适宜人群筛选  

Investigation for the adenovirus type 5 immunity in children population under the age of 12 in the eastern part of China （For screening population who are suitable for using Ad5-based recombinant vector vaccines or gene therapy agents）

作　　者：马春玲 董立 钟天鹰[2] 王世霞[3] 卢山[3] 

机构地区：[1]山东医学高等专科学校免疫学实验室,山东临沂276002 [2]南京市儿童医院检验科 [3]江苏省人民医院中美疫苗研究中心,江苏南京210029

出　　处：《世界感染杂志》2010年第3期109-112,共4页World Journal of Infection

基　　金：山东省教育厅科技计划项目（J07YE06）;山东省医药卫生科技发展计划项目（2007HW134）

摘　　要：目的调查12岁以下儿童腺病毒（adenovirus，Ad）感染所诱发的免疫力状况，尤其是针对5-型腺病毒（Ad5）的免疫力状况，旨在筛选应用Ad5重组疫苗和基因治疗剂的适宜人群。方法通过采集华东部分省市和地区12岁以下儿童的血清标本，采用ELISA方法检测Ad非特异性总抗体（Ad Total antibody，Ad-TAb），用蚀斑减少中和试验（Plague Reduction Neutralization Test，PRNT）来检测Ad5中和抗体（Ad5 neutralizing antibody，Ad5-NAb），用Stata9．0软件进行数据分析。结果经过ELISA和PRNT检测，发现Ad-TAb和Ad5-NAb的滴度水平以及各组标本的阳性率，均随着年龄的增长而呈上升的趋势。以低于2岁的年龄组各项数据最低，与其它各组有显著性差异（P〈0．05）。结论在12岁以下儿童人群中，以低于2岁的年龄组应用Ad5型重组疫苗或基因治疗剂是可行的。Objective To investigate the adenovirus （adenovirus, Ad） infection-induced immunity in the children who are below 12 years old, especially for the immunity condition of adenovirus serotype 5 （Ad5）. Methods Serum samples were collected from children under the age of 12 in the eastern regions of China, and detected by using ELISA for total antibodies of adenovirus （Ad-Tab）, and by using the plaque reduction neutralization test （PRNT） for Ad5 neutralizing antibodies （Ad5-NAb）. Stata 9.0 software was used for data analysis. Results After ELISA and PRNT assay, the titer levels of Ad-TAb and Ad5-NAb, and positive rates of each group of specimens are found to be in the upward trends while with age increasing. The data of below 2-year-old age group is the lowest among these four group after statistical analysis. Conclusions In this study, we found that younger than 2-year-old age is suitable for application of Ad5-based recombinant vaccine or gene therapeutic agents.

关 键 词：腺病毒 5-型腺病毒 非特异性总抗体 中和抗体 酶联免疫吸附试验 蚀斑减少中和试验 

分 类 号：R511.8[医药卫生—内科学] R446.6[医药卫生—临床医学]